Palladio Biosciences   Report issue

For profit Phase 3
Founded: Newtown PA United States (2015)
Status: Acquired by Centessa (2021)

Organization Overview

First Clinical Trial
2018
NCT03487913
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Palladio Biosciences